SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Panel to Review Abbott Laboratories’s Meridia on Sept. 15, 2010

August 6, 2010 | 
1 min read

Reuters -- Abbott Laboratories’ (ABT.N) weight loss drug Meridia will be reviewed by an advisory panel to the U.S. Food and Drug Administration on September 15, the company said on Friday.

Regulatory
Food and Drug Administration (FDA) Abbott Laboratories
MORE ON THIS TOPIC
The EMA's former headquarters in London
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Editorial
Transparency Missing in Action at HHS Despite Leaders’ Calls for Clarity
February 28, 2025
 · 
4 min read
 · 
Heather McKenzie
Pictured: Regeneron logo on a light brown building
Lymphoma
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: A syringe broken in half with long hallway in background/Nicole Bean for BioSpace
Vaccines
Meeting of FDA’s Vaccines Advisory Panel Canceled as Kennedy Settles Into HHS
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac